Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–57.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.

Article  PubMed  Google Scholar 

Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Sci Transl Med. 2016;8:323rv1.

Article  PubMed  Google Scholar 

Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27:22–41.

Article  CAS  PubMed  Google Scholar 

Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the middle East and north Africa: data from global burden of disease 2009-2019. J Hepatol. 2021;75:795–809.

Article  CAS  PubMed  Google Scholar 

Andreasen CR, Andersen A, Vilsbøll T. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023;66:1846–58.

Article  CAS  PubMed  Google Scholar 

Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–46.

Article  CAS  PubMed  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol J Ger Card Soc. 2021;110:921–37.

Google Scholar 

Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022;11:968.

Article  PubMed  PubMed Central  Google Scholar 

Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021;2021:6613827.

Article  PubMed  PubMed Central  Google Scholar 

Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345–53.

Article  CAS  PubMed  Google Scholar 

Greve S, Kuhn GA, Saenz-de-Juano MD, Ghosh A, von Meyenn F, Giller K. The major urinary protein gene cluster knockout mouse as a novel model for translational metabolism research. Sci Rep. 2022;12:13161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pallauf K, Günther I, Chin D, Rimbach G. In contrast to dietary restriction, application of resveratrol in mice does not alter mouse major urinary protein expression. Nutrients. 2020;12:815.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, Jiang L, Rui L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. J Biol Chem. 2009;284:11152–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao R, Wang H, Li T, Wang J, Ren Z, Cai N, et al. Secreted MUP1 that reduced under ER stress attenuates ER stress induced insulin resistance through suppressing protein synthesis in hepatocytes. Pharmacol Res. 2023;187:106585.

Article  CAS  PubMed  Google Scholar 

Zhang H, Li C, Han L, Xiao Y, Bian J, Liu C, et al. MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis. Gut Microbes. 2024;16:2367342.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Wu X, Xu M, Yue T, Ling P, Fang T, et al. Comparative proteomic pnalysis of liver tissues and serum in db/db mice. Int J Mol Sci. 2022;23:9687.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szoka PR, Gallagher JF, Held WA. In vitro synthesis and characterization of precursors to the mouse major urinary proteins. J Biol Chem. 1980;255:1367–73.

Article  CAS  PubMed  Google Scholar 

Dhahbi JM, Kim HJ, Mote PL, Beaver RJ, Spindler SR. Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proc Natl Acad Sci USA. 2004;101:5524–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giller K, Huebbe P, Doering F, Pallauf K, Rimbach G. Major urinary protein 5, a scent communication protein, is regulated by dietary restriction and subsequent re-feeding in mice. Proc Biol Sci. 2013;280:20130101.

CAS  PubMed  PubMed Central  Google Scholar 

Chen CC, Lee TY, Kwok CF, Hsu YP, Shih KC, Lin YJ, et al. Major urinary protein 1 interacts with cannabinoid receptor type 1 in fatty acid-induced hepatic insulin resistance in a mouse hepatocyte model. Biochem Biophys Res Commun. 2015;460:1063–8.

Article  CAS  PubMed  Google Scholar 

Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Hsieh MH, et al. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. J Formos Med Assoc. 2020;119:89–96.

Article  PubMed  Google Scholar 

Yao Z, Gong Y, Chen W, Shao S, Song Y, Guo H, et al. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. Nat Metab. 2023;5:1706–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509–20.

Article  CAS  PubMed  Google Scholar 

Lu M, Wan M, Leavens KF, Chu Q, Monks BR, Fernandez S, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18:388–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 2008;8:65–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197–211.

Article  CAS  PubMed  PubMed Central